CurrentCignaPolicy IP0336

Hereditary Angioedema - Kalbitor (ecallantide)

Defines Cigna prior authorization, coverage criteria, dosing limits, and documentation requirements for Kalbitor (ecallantide) to treat acute hereditary angioedema (HAE) due to C1-INH deficiency in covered members.

Policy Summary

PayerCigna

PolicyHereditary Angioedema - Kalbitor (ecallantide)

Policy CodePolicy IP0336

Key ActionPrior authorization is required; approve for 1 year if coverage criteria and documentation (including baseline functional C1‑INH <50% and low serum C4) are met.

Change TypeCriteria revised and diagnostic requirements updated

Effective Date

Next Review Date

SourceLink

POLICY UPDATE CHANGES

Added 'Due to C1 Inhibitor (C1-INH) Deficiency' to indication name.

Revised diagnostic requirement to require HAE type I or II confirmed by low functional C1-INH (<50% of normal) and low serum C4 at baseline; specified that HAE with normal C1-INH (type III) does not satisfy requirement.

Removed requirement for confirmed pathogenic variant in SERPING1, F12, ANGPT1, PLG or KNG1 genes.

Removed prior criterion requiring low C1-INH antigenic levels (<50%) at baseline (antigenic specifically).

Added criterion allowing approval for patients who have previously treated acute HAE attacks with Kalbitor, with continuation criteria.

≥12 yrsFDA min age

1 yrStandard approval

30 mgMax dose

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Kalbitor (ecallantide)

FDA-Approved Indication — Initial Therapy

Approve Kalbitor for 1 year if the patient meets ALL of the following for initial therapy:

Diagnostic confirmation (i): Patient has HAE type I or type II confirmed by (a) low functional C1-INH (<50% of normal) at baseline AND (b) low serum C4 at baselinefunctional C1-INH <50% of normal; serum C4 lower than normal per laboratory reference values

A diagnosis of HAE with normal C1-INH (HAE type III) does NOT satisfy this requirement.

Specialist requirement (ii): Medication is prescribed by, or in consultation with, an allergist/immunologist or a physician who specializes in treatment of HAE or related disorders

Preferred product criteria (iii): Preferred product criteria for the product as listed in plan-specific tables must be met

See Employer or Individual & Family plan tables for specifics.

FDA-Approved Indication — Continuation / Prior Use

Approve Kalbitor for 1 year if the patient meets ALL of the following for continuation/prior-use:

Continuation / Prior-use criteria: (i) Patient has a diagnosis of HAE type I or type II; AND (ii) According to the prescriber, the patient has had a favorable clinical response to Kalbitor; AND (iii) Medication is prescribed by, or in consultation with, an allergist/immunologist or a physician who specializes in treatment of HAE or related disorders

If the patient is currently receiving the requested therapy but has not previously received approval of Kalbitor through Coverage Review, review under Initial Therapy criteria.

Plan-specific Preferred Product / Step Criteria

Employer Plans and Individual & Family Plans include additional criteria — meet one of the following:

Employer Plans: Patient meets one of: (1) Patient less than 18 years; OR (2) Patient has previously treated an acute HAE attack with Kalbitor; OR (3) Patient has tried generic icatibant

A previous trial of any icatibant product counts toward Criterion 3.

Individual & Family Plans: Patient meets one of: (1) Patient less than 18 years; OR (2) Patient has previously treated an acute HAE attack with Kalbitor; OR (3) Patient has tried generic icatibant or Sajazir

A previous trial of any icatibant product counts toward Criterion 3.

Kalbitor (ecallantide) for prophylaxis of hereditary angioedema (HAE) attacks or for any other use that is not approved by the FDA is considered not medically necessary. This includes use for HAE prophylaxis, for which data are not available and Kalbitor is not indicated.

Use of Kalbitor for HAE prophylaxis is specifically listed as not medically necessary because there are no available data supporting prophylactic use; other unspecified non‑FDA‑approved indications are likewise considered not medically necessary and may be denied.

Coding and Clinical Thresholds

Considered Medically Necessary when criteria metHCPCSCovered

J1290

Injection, ecallantide, 1 mg

Functional C1-INH — clinical threshold value

Functional C1-INH thresholdFunctional C1-INH < 50% of normal (baseline), per laboratory reference values; documentation required

ContextRequired to confirm HAE type I or II; HAE with normal C1-INH (type III) does NOT satisfy this requirement

DocumentationBaseline laboratory record showing functional C1-INH level required for prior authorization

Serum C4 — clinical threshold value

Serum C4 thresholdSerum C4 lower than normal at baseline, per laboratory reference values; documentation required

PurposeUsed alongside functional C1-INH to confirm HAE type I or II; HAE type III does NOT meet criteria

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required; approve for 1 year when criteria met

Prior authorization is required for Kalbitor. If the patient meets the applicable coverage criteria, approve the request for a duration of 1 year for either initial therapy or continuation/prior-use.

All approvals are provided for the duration noted (1 year) when criteria are met.
Requests for doses outside established dosing will be considered case-by-case by a clinician.

Step Therapy

Plan-specific step/preferred product criteria (Employer & Individual/Family)

For Employer and Individual & Family plans, the patient must meet one of the plan-specific preferred product/step criteria: age <18 years, prior treatment of an acute HAE attack with Kalbitor, or trial of generic icatibant (Individual & Family plans also accept Sajazir).

Employer Plans: 1) Patient < 18 years; OR 2) Previously treated an acute HAE attack with Kalbitor; OR 3) Tried generic icatibant.

Background on Kalbitor and HAE

Kalbitor (ecallantide) is a plasma kallikrein inhibitor indicated for treatment of acute hereditary angioedema (HAE) attacks in patients aged ≥ 12 years. The policy clarifies that the covered indication is specifically for HAE due to C1‑inhibitor (C1‑INH) deficiency (type I or II), diagnosed by laboratory confirmation of low functional C1‑INH and low serum C4 at baseline; a diagnosis of HAE with normal C1‑INH (type III) does not meet the diagnostic requirement. The drug carries a risk of hypersensitivity/anaphylaxis and should be administered where anaphylaxis can be recognized and managed.

Definitions

Hereditary angioedema due to C1-INH deficiency — diagnostic definition

Definition (HAE type I/II)Hereditary angioedema due to C1-INH deficiency confirmed by low functional C1-INH (<50% of normal) and low serum C4 at baseline.

ExclusionHAE with normal C1-INH (also known as HAE type III) does NOT satisfy this diagnostic requirement.

DocumentationBaseline laboratory records showing functional C1-INH <50% and low serum C4 are required for prior authorization.

Use caseRequired to establish eligibility for Kalbitor for treatment of acute HAE attacks due to C1-INH deficiency.

Policy Summary

PayerCigna

PolicyHereditary Angioedema - Kalbitor (ecallantide)

Policy CodePolicy IP0336

Key ActionPrior authorization is required; approve for 1 year if coverage criteria and documentation (including baseline functional C1‑INH <50% and low serum C4) are met.

Change TypeCriteria revised and diagnostic requirements updated

Effective Date

Next Review Date

SourceLink

On This Page

DocumentationBaseline serum C4 laboratory result must be provided for coverage determination

Maximum dose per injection — 30 mg

Maximum dose per injection30 mg per injection (subcutaneous)

IndicationDose limit applies to treatment of acute HAE attacks with Kalbitor

DocumentationPrescribers should document dosing on claims consistent with the 30 mg per injection limit

Maximum dosing frequency — clinical limit

Maximum dosing frequencyNo more frequently than twice daily (subcutaneous administration)

Dose schedulingAdhere to maximum of two injections per day when treating acute HAE attacks

Coverage implicationRequests exceeding twice-daily administration may be denied as not meeting dosing criteria

Individual & Family Plans: 1) Patient < 18 years; OR 2) Previously treated an acute HAE attack with Kalbitor; OR 3) Tried generic icatibant or Sajazir.

Documentation Required

Required documentation — baseline labs and chart notes

Documentation must include baseline laboratory records confirming HAE type I/II: functional C1‑INH <50% of normal and lower-than-normal serum C4, as defined by laboratory reference values; include chart notes and patient identifiers.

Functional C1‑INH < 50% of normal at baseline (per laboratory reference values) [documentation required].
Lower-than-normal serum C4 at baseline (per laboratory reference values) [documentation required].
Documentation may include chart notes, laboratory records, and prescription claims records and must include patient-specific identifying information.

Documentation Required

Continuation documentation — prescriber attestation of favorable response required

For continuation approvals, provide documentation from the prescriber that the patient has had a favorable clinical response to Kalbitor treatment.

Examples of favorable clinical response include decreased duration of attacks, quick symptom relief, complete resolution of symptoms, or decreased attack frequency/severity.
If the patient is currently receiving therapy but has not previously received approval through Coverage Review, initial therapy criteria must be met.

Denial Risk

Denial risk — missing/incorrect codes or unmet policy criteria

Claims submitted without covered diagnosis/procedure codes or that do not meet the Coverage Policy criteria will be denied as not covered.

When billing, providers must use the most appropriate codes as of the effective date of submission.
Reimbursement is not allowed for services billed for conditions or diagnoses not covered under this Coverage Policy.

Denial Risk

Not medically necessary uses — prophylaxis and other non‑approved indications

Use of Kalbitor for prophylaxis of HAE attacks or for any other non–FDA‑approved use is considered not medically necessary and may be denied.

HAE prophylaxis: data are not available and Kalbitor is not indicated for prophylaxis of HAE attacks.
Kalbitor for any other use not listed in the FDA‑approved indication may be considered not medically necessary.